TOI maintains strong 2026 outlook with $630M-$650M revenue guidance. The company achieved its first positive adjusted EBITDA in Q4 2025 while delivering impressive 42% revenue growth year-over-year. Notably, TOI is expanding delegated capitation partnerships, a strategic move that diversifies revenue streams beyond traditional models. The pharmacy expansion initiative signals management's confidence in operational scalability and market positioning. Reaching positive adjusted EBITDA represents a critical milestone for the company, demonstrating improved operational efficiency and path to sustained profitability. These developments suggest TOI is executing effectively on its growth strategy while maintaining financial discipline. Investors should monitor capitation partnership progress and pharmacy segment performance as key metrics for validating 2026 guidance achievement.
Post from MarketNews_en
Log in to interact with content.